Summit Therapeutics stock hits 52-week low at 12.23 USD
Summit Therapeutics PLC’s stock has reached a 52-week low, trading at $12.31, just above its 52-week low of $12.25 and down sharply from its 52-week high of $30.05. According to an InvestingPro tip, the stock has taken a big hit over the last week, declining over 10%.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
Summit Therapeutics PLC’s stock has reached a 52-week low, trading at $12.31, just above its 52-week low of $12.25 and down sharply from its 52-week high of $30.05. According to an InvestingPro tip, the stock has taken a big hit over the last week, declining over 10%. Over the past year, the company’s stock has experienced a significant decline, with a 1-year change of approximately -50%. Despite this downturn, InvestingPro analysis suggests the stock appears undervalued at current levels.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Summit Therapeutics PLC’s stock has reached a 52-week low, trading at $12.31, just above its 52-week low of $12.25 and down sharply from its 52-week high of $30.05. According to an InvestingPro tip, the stock has taken a big hit over the last week, declining over 10%.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 16m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Summit Therapeutics stock hits 52-week low at 12.23 USD
Sources1TypeCoverageInvesting.com · Company News